08:00 , Dec 21, 2015 |  BC Week In Review  |  Clinical News

S48168 regulatory update

FDA granted rare pediatric disease and Orphan Drug designation to ARM210 from Armgo to treat Duchenne muscular dystrophy (DMD). ARM210 is in Phase I testing for DMD. The product is an oral Rycal, a small...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Company News

Intezyne management update

Intezyne Technologies Inc. , Tampa, Fla.   Business: Cancer   Hired: Tim Coan as CFO, formerly a partner at Deerfield Partners; and Carolyn Paradise as acting CMO, formerly president and COO of Armgo Pharma Inc....
07:00 , Sep 20, 2012 |  BC Innovations  |  Targets & Mechanisms

Stabilizing RyR2

A group at Columbia University has found that preventing the leak of calcium ions from ryanodine receptors could help treat post-traumatic stress disorder, and a French team has found that the strategy could be effective...
07:00 , Sep 13, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Post-traumatic stress disorder Ryanodine receptor 2 (RyR2) Mouse studies suggest stabilizing RyR2 could help prevent post-traumatic stress disorder. In mice, an RyR2-stabilizing protein prevented chronic...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Clinical News

Armgo preclinical data

In a mouse model of stress-induced cognitive dysfunction, oral S107 significantly improved learning and memory as measured by the Morris water maze test (p<0.05) and the novel object recognition test (p<0.05) vs. untreated stressed control...
07:00 , Sep 6, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Ryanodine receptor 1 (RyR1) In vitro and mouse studies suggest inhibiting RyR1 could help treat AD. In neuroblastoma cell lines and mouse...
08:00 , Jan 19, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Other

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Hyperthermia Ryanodine receptor 1 (RyR1) Mouse studies suggest 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) could help prevent heat-induced sudden death caused by RyR1 mutations....
08:00 , Nov 7, 2011 |  BioCentury  |  Strategy

Servicing CV

While some pharmas have concluded cardiovascular disease is well served by generics and are exiting the space, Servier believes it can grow its CV business by in-licensing novel, first-in-class programs. Last month, Servier agreed to...
07:00 , Aug 29, 2011 |  BC Week In Review  |  Financial News

Armgo completes venture financing

Armgo Pharma Inc. , Tarrytown, N.Y.   Business: Cardiovascular, Musculoskeletal   Date completed: 8/12/11   Type: Venture financing   Raised: $1 million  ...
07:00 , May 9, 2011 |  BC Week In Review  |  Company News

Armgo management update

Armgo Pharma Inc. , Tarrytown, N.Y.   Business: Cardiovascular, Musculoskeletal   Hired: Sapan Shah as CEO and a director, formerly CEO and president at Shionogi & Co. Ltd. 's Shionogi Inc. subsidiary  ...